Single-Inhaler Triple Therapy (SITT) for COPD: An Italian expert opinion paper on improving clinical outcomes and equity of therapeutic access
Keywords:
Chronic Obstructive Pulmonary Disease (COPD), Multiple-Inhaler Triple Therapy (MITT), Single-Inhaler Triple Therapy (SITT), AIFA Note 99, treatment adherence, healthcare access equityAbstract
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of global morbidity and mortality, with significant burden in Italy. Prevalence estimates vary by data source: Health Search data indicate a prevalence of 2.7% among adults, whereas population-based analyses report higher estimates of approximately 5.6%. Triple therapy combining a long-acting muscarinic antagonist (LAMA), a long-acting beta2-agonist (LABA), and an inhaled corticosteroid (ICS) has been shown to improve lung function, reduce exacerbations, and potentially decrease mortality in moderate-to-severe COPD. Fixed-dose Single-Inhaler Triple Therapy (SITT) provides practical advantages over Multiple-Inhaler Triple Therapy (MITT), including improved treatment adherence, fewer inhaler technique errors, and comparable safety. This expert opinion review summarizes evidence from randomized controlled trials and real-world studies supporting the clinical, practical, and economic benefits of SITT.
While access to SITT in Italy is influenced by regulatory frameworks, optimizing prescription practices and aligning treatment strategies with clinical evidence could enhance continuity of care and patient outcomes. The paper highlights strategies to improve COPD management, reduce treatment discontinuation, and ensure equitable access to effective therapies.
References
1. Celli BR, Wedzicha JA. Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med 2019;381:1257-66.
2. Confalonieri M, Braga L, Salton F, Ruaro B, Confalonieri P. Chronic Obstructive Pulmonary Disease Definition: is it time to incorporate the concept of failure of lung regeneration? Am J Respir Crit Care Med 2023;207:366-7.
3. World Health Organization (WHO). The top 10 causes of death 2024. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (2024).
4. Società Italiana dei Medici di Medicina Generale e delle Cure Primarie (S.I.M.G.) XVI Report Health Search Edizione 2023. https://www.simg.it/hs-report/XVI.pdf (2023).
5. Calabria S, Ronconi G, Dondi L, Pedrini A, Piccinni C, Esposito I, et al. Real-world analysis of obstructive respiratory tract disorders: characterization, health care and costs. Recenti progressi in medicina 2021;112:285-93.
6. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022;10:497-511.
7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73.
8. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2025 Report. https://goldcopd.org/2025-gold-report/ (2025).
9. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96.
10. Darbà J, Ramírez G, Sicras A, Francoli P, Torvinen S, Sánchez-de la Rosa R. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients. Int J Chron Obstruct Pulmon Dis 2015;10:2335-45.
11. Melani AS, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011;105:930-8.
12. Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388:963-73.
13. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018;378:1671-80.
14. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to- very-severe COPD. N Engl J Med 2020;383:35-48.
15. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391:1076-84.
16. Agenzia Italiana del Farmaco DETERMINA 24 agosto 2018 - Classificazione del medicinale per uso umano «Trimbow», ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 1358/2018). (18A05984) (GU Serie Generale n.218 del 19-09-2018); Articolo 3. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2018-09-19&atto.codiceRedazionale=18A05984&elenco30giorni=false (2018)
17. Agenzia Italiana del Farmaco DETERMINA 19 febbraio 2019 - Riclassificazione del medicinale per uso umano «Trelegy Ellipta», ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 288/2019). (19A01476) (GU Serie Generale n.58 del 09-03-2019); Articolo 3. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2019-03-09&atto.codiceRedazionale=19A01476&elenco30giorni=true (2019)
18. Agenzia Italiana del Farmaco DETERMINA 10 gennaio 2022 - Riclassificazione del medicinale per uso umano «Trixeo Aerosphere», ai sensi dell'articolo 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. 2/2022). (22A00192) (GU Serie Generale n.8 del 12-01-2022); Articolo 3. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2022-01-12&atto.codiceRedazionale=22A00192&elenco30giorni=true (2022)
19. Agenzia Italiana del Farmaco. Nota 99. https://www.aifa.gov.it/documents/20142/1728122/nota-99.pdf (2022).
20. González-González MA, Pedrosa-Naudín MA, Fernández-Lázaro D, Planelles ID, Álvarez FJ, Gutiérrez-Abejón E. Single-versus multiple-inhaler triple therapy in patients with COPD in Spain: a retrospective cohort study comparing adherence, persistence, risk of exacerbations and economic outcomes. Front Pharmacol 2025;16:1642470.
21. Di Marco F, Shahaj O, Valipour A, Legrand B, Jommi C, Micheletto C, et al. Single-Inhaler Triple Therapy in Primary Care Across Europe: Expert Panel Consensus on the Consequences of Payer-Driven Access Rules and Call to Action. Int J Chron Obstruct Pulmon Dis 2025;20:1595-612.
22. Bourbeau J, Bhutani M, Hernandez P, Aaron SD, Beauchesne MF, Kermelly SB, et al. 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients with Stable COPD. Chest 2023;164:1159-83.
23. Halpin DMG, Worsley S, Ismaila AS, Beeh KM, Midwinter D, Kocks JWH, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res 2021;7:00950-2020.
24. Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J, Juárez M, Graefenhain R, Sicras-Mainar A. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple- inhaler triple therapy: a retrospective analysis in Spain. Chest 2022;162:1017-29.
25. Halpin DMG, Rothnie KJ, Banks V, Czira A, Compton C, Wood R, et al. Comparative adherence and persistence of single- and multiple- inhaler triple therapies among patients with chronic obstructive pulmonary disease in an English real-world primary care setting. Int J Chron Obstruct Pulmon Dis 2022;17:2417-29.
26. Deslee G, Fabry-Vendrand C, Poccardi N, Thabut G, Eteve Pitsaer C, et al. Use and persistence of single and multiple inhaler triple therapy prescribed for patients with COPD in France: a retrospective study on THIN database (OPTI study). BMJ Open Respir Res 2023;10:e001585.
27. Steiropoulos P, Georgatou N, Krommidas G, Bartziokas K, Korkontzelou A, Katerelos P, Efstathopoulos P, et al. Extrafine single inhaler triple therapy effectiveness in COPD patients previously treated with multiple-inhaler triple therapy: the TRIWIN study. Ther Adv Respir Dis 202;18:17534666241263439.
28. Cabrer CE, López García J, Vega Lizarazo DE, Benítez-Cano Gamonoso M, Segura Romero M, Sanchez Martín S, et al. Inhaled Triple Therapy with Extrafine Single Inhaler Versus Multiple Devices in Chronic Obstructive Pulmonary Disease (TRIPOLI): A Post-Authorization Retrospective Study. Int J Chron Obstruct Pulmon Dis 2025;20:1737-47.
29. Vogelmeier CF, Beeh KM, Schultze M, Kossack N, Richter LM, Claussen J, et al. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study. Int J Chron Obstruct Pulmon Dis 2024;19:1835-48.
30. National Institute for Health and Care Excellence (NICE). Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis and Management. NICE Guideline, No. 115. https://www.nice.org.uk/guidance/ng115 (2019).
31. Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd CM, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med 2020;201:e56-e69. Erratum in: Erratum: Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;202:910.
32. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial. Lancet 201;389:1919-29.
33. Soumagne T, Zysman M, Karadogan D, Lahousse L, Mathioudakis AG. Impact of triple therapy on mortality in COPD. Breathe (Sheff) 2023;19:220260.
34. US Food and Drug Administration. Final Summary Minutes of the Pulmonary-Allergy Drugs Advisory Committee Meeting, August 31, 2020 https://www.regulations.gov/document/FDA-2020-N-0626-0003 (2020).
35. US Food and Drug Administration. Warning Letter: AstraZeneca Pharmaceuticals LP. MARCS-CMS 664789 – August 04, 2023. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/astrazeneca-pharmaceuticals-lp-664789-08042023 (2023).
36. Haidich AB. Meta-analysis in medical research. Hippokratia 2010;14:29-37.
37. Lee HW, Park J, Jo J, Jang EJ, Lee CH. Comparisons of exacerbations and mortality among regular inhaled therapies for patients with stable chronic obstructive pulmonary disease: Systematic review and Bayesian network meta-analysis. PLoS Med 2019;16:e1002958.
38. Axson EL, Lewis A, Potts J, Pang M, Dickinson S, Vioix H, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open 2020;10:e036455.
39. Koarai A, Yamada M, Ichikawa T, Fujino N, Kawayama T, Sugiura H. Triple versus LAMA/LABA combination therapy for patients with COPD: a systematic review and meta-analysis. Respir Res 2021;22:183.
40. Chen H, Deng ZX, Sun J, Huang Q, Huang L, He YH, et al. Association of Inhaled Corticosteroids with All-cause Death Risk in COPD Patients: A Meta-analysis of Sixty Randomized Controlled Trials. Chest 2023;63:100-14.
41. Pan Q, Sun J, Gao S, Liu Z, Huang Y, Lian Y. Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis. Arch Med Sci 2024;20:1586-96.
42. Calderón-Montero A, García Fernández M, García-Velasco ME, Joshi M, Khan K, Calderón-Ferrer C, et al. Effect of triple inhaled therapy on cardiovascular and all-cause mortality compared with dual inhaled therapy in COPD: A systematic review and meta-analysis. Semergen 2025;51:102478.
43. Li Y, Li J, Yang H, Zhang Y. Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD: a meta-analysis of randomized controlled trials. BMC Pulm Med 2025;25:345.
44. Long H, Xu H, Janssens JP, Guo Y. Single-inhaler triple vs single-inhaler dual therapy in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized control trials. Respir Res 2021;22:209.
45. Lai CC, Chen CH, Chen KH, Wang CY, Huang TM, Wang YH, et al. The Impact of 52 Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Life (Basel) 2022;12:173.
46. van Geffen WH, Tan DJ, Walters JA, Walters EH. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2023;12:CD011600.
47. Hammadi A, Hoyas-Sánchez C, Romero-Linares A, Álvarez-Muro L, Menéndez-Lobo A, Romeral-Navarro D, et al. All-Cause and Cardiovascular Mortality With Single Inhaler Triple Therapy Versus Double Therapies for COPD: A Systematic Review and Metanalysis. Arch Bronconeumol 2025;61:594-602.
48. Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther 2018;35:1763-74.
49. Rogliani P, Manzetti GM, Cazzola M, Calzetta L. Real-World Effectiveness of Triple Extrafine Fixed-Dose Combination with Beclomethasone/Formoterol/Glycopyrronium on Symptoms and Lung Function in COPD: A Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis 2025;20:1723-36.
50. Murad MH, Montori VM. Synthesizing evidence: shifting the focus from individual studies to the body of evidence. JAMA 2013;309:2217-8.
51. Poehling GG, Jenkins CB. Levels of evidence and your therapeutic study: what’s the difference with cohorts, controls, and cases? Arthroscopy 200;20:563..
52. Lucas RM, Rodney Harris RM. On the Nature of Evidence and 'Proving' Causality: Smoking and Lung Cancer vs. Sun Exposure, Vitamin D and Multiple Sclerosis. Int J Environ Res Public Health 2018;15:1726.
53. Richeldi L, Schino P, Bargagli E, Ricci A, Rocca A, Marchesani F, et al. TRITRIAL: The Impact of Fixed Triple Therapy with Beclometasone/Formoterol/Glycopyrronium on Health Status and Adherence in Chronic Obstructive Pulmonary Disease in an Italian Context of Real Life. Int J Chron Obstruct Pulmon Dis 2024;19:475-87.
54. Beeh KM, Scheithe K, Schmutzler H, Krüger S. Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial. Int J Chron Obstruct Pulmon Dis 202;19:205-16.
55. Gessner C, Trinkmann F, Bahari Javan S, Hövelmann R, Bogoevska V, Georges G, et al. Effectiveness of Extrafine Single Inhaler Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) in Germany - The TriOptimize Study. Int J Chron Obstruct Pulmon Dis 2022;17:3019-31.
56. Brusselle G, Himpe U, Fievez P, Leys M, Perez Bogerd S, Peché R, et al. Evolving to a single inhaler extrafine LABA/LAMA/ICS - Inhalation technique and adherence at the heart of COPD patient care (TRIVOLVE). Respir Med 2023;218:107368.
57. Porpodis K, Bartziokas K, Chatziapostolou P, Korkontzelou A, Katerelos P, Efstathopoulos P, et al. Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study - The TRIBUNE study. Respir Med 2023;212:107219.
58. Marth K, Renner A, Pohl W. TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD. Respir Med 2021;182:106398.
59. Lim H, Kim DH, Hong SH, Shin J, Lee H, Shin K, et al. Real-world effectiveness of single-inhaler triple treatment through assorted respiratory outcomes when switched from multiple-inhaler triple therapies (RESTART): a prospective cohort study of Korean patients with COPD. Int J Chron Obstruct Pulmon Dis 2025;20:1039-50.
60. Roche N, Anzueto A, Bosnic Anticevich S, Kaplan A, Miravitlles M, Ryan D, et al. The importance of real-life research in respiratory medicine: manifesto of the respiratory effectiveness group: endorsed by the international primary care respiratory group and the world allergy organization. Eur Respir J 2019;54:1901511.
61. Zhang L, Wang X, Zhang Y, Chen W. Efficacy and Safety of Single Inhaler Triple Therapy Versus Separate Triple Therapy in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. Clin Ther 2022;44:859-73.
62. Turégano-Yedro M, Trillo-Calvo E, Navarro I Ros F, Maya-Viejo JD, González Villaescusa C, Echave Sustaeta JM, et al. Inhaler Adherence in COPD: A Crucial Step Towards the Correct Treatment. Int J Chron Obstruct Pulmon Dis 2023;18:2887-93.
63. Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei Farmaci in Italia. Rapporto Nazionale Anno 2021. Roma: Agenzia Italiana del Farmaco https://www.aifa.gov.it/documents/20142/1740782/Rapporto-OsMed-2021.pdf (2022).
64. Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. Int J Chron Obstruct Pulmon Dis 2019;14:343-52.
65. Zucchelli A, Vetrano DL, Bianchini E, Lombardo FP, Piraino A, Zibellini M, et al. Adherence to COPD free triple inhaled therapy in the real world: a primary care-based study. Clin Respir J 2020;14:732-9.
66. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008;11:44-7.
67. Restrepo RD, Alvarez MT, Wittnebel LD, Sorenson H, Wettstein R, Vines DL, et al. Medication adherence issues in patients treated for COPD. Int J Chron Obstruct Pulmon Dis 2008;3:371-84.
68. Jokšaitė S, Wood R, Ismaila A, Camidge L, Mizukami A, Czira A, et al. Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study. BMJ Open 2024;14:e080864.
69. Lin L, Liu C, Cheng W, Song Q, Zeng Y, Li X, et al. Comparison of treatment persistence, adherence, and risk of exacerbation in patients with COPD treated with single-inhaler versus multiple-inhaler triple therapy: A prospective observational study in China. Front Pharmacol 2023;14:1147985.
70. Mannino D, Bogart M, Wu B, Germain G, Laliberté F, MacKnight SD, et al. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study. Respir Med 2022;197:106807.
71. Pollack M, Rapsomaniki E, Anzueto A, Rhodes K, Hawkins NM, Vogelmeier CF, et al. Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study. Am J Med 2025;138:650-9.e10.
72. Usmani OS, Lavorini F, Marshall J, Dunlop WCN, Heron L, Farrington E, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res 2018;19:10.
73. Sanchis J, Gich I, Pedersen S. Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest 2016;150:394-406.
74. Bosnic-Anticevich S, Chrystyn H, Costello RW, Dolovich MB, Fletcher MJ, Lavorini F, et al. The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2016;12:59-71. Erratum in: The use of multiple respiratory inhalers requiring different inhalation techniques has an adverse effect on COPD outcomes [Corrigendum]. Int J Chron Obstruct Pulmon Dis 2019;14:1739.
75. Roggeri A, Micheletto C, Roggeri DP. Inhalation errors due to device switch in patients with chronic obstructive pulmonary disease and asthma: critical health and economic issues. Int J Chron Obstruct Pulmon Dis 2016;11:597-602.
76. Sulku J, Bröms K, Högman M, Janson C, Lisspers K, Malinovschi A, et al. Critical inhaler technique errors in Swedish patients with COPD: a cross-sectional study analysing video-recorded demonstrations. NPJ Prim Care Respir Med 2021;31:5.
77. Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, Calzetta L. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol 2020;177:1150-63.
78. Rogliani P, Ritondo BL, Facciolo F, Matera MG, Nikolaev I, Calzetta L. Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways. Pharmacol Res 2021;172:105801.
79. Rogliani P, Ora J, Frugoni C, Melis E. Facciolo F, Calzetta L. Modulating the Level of ICS in Triple ICS/LABA/LAMA FDC: Effect Against Airway Hyperresponsiveness in a Human Ex Vivo Model of Severe Eosinophilic Asthma. Am J Respir Crit Care Med 2023;207:A1311.
80. Cançado JED, Usmani OS. Choice of inhaler device and its disposal have a significant impact on the environment. J Bras Pneumol 2024;50;e20240092.
81. Sposato B, Ricci A, Lacerenza LG, Petrucci E, Cresti A, Baratta P, et al. Triple Therapy in COPD in Real Life: Is It Better to Use Single or Multiple Inhalers? J Clin Med 2024;13:6191.
82. Ministero della Salute. Piano Nazionale della Cronicità (PNC). https://www.quotidianosanita.it/allegati/allegato1721737583.pdf (2024).
83. Istituto Superiore di Sanità. EpiCentro - L’epidemiologia per la sanità pubblica. Broncopneumopatia cronica ostruttiva. https://www.epicentro.iss.it/broncopneumopatia/
84. CittadinanzAttiva, 2022. XX Rapporto sulle politiche della cronicità – Fermi al piano. https://www.cittadinanzattiva.it/comunicati/15423-presentato-il-xx-rapporto-nazionale-sulle-politiche-della-cronicita-fermi-al-piano.html (2022).
85. Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2022. Roma: Agenzia Italiana del Farmaco. https://www.aifa.gov.it/documents/20142/1967301/Rapporto-OsMed-2022.pdf (2023).
86. Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med 2013;107:1481-90.
87. Ismaila A, Corriveau D, Vaillancourt J, Parsons D, Dalal A, Su Z, et al. Impact of adherence to treatment with tiotropium and fluticasone propionate/salmeterol in chronic obstructive pulmonary diseases patients. Curr Med Res Opin 2014;30:1427-36.
88. Vestbo J, Anderson JA, Calverley PM, Celli B, Ferguson GT, Jenkins C, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax 2009;64:939-43.
89. Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, et al. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486-96.
90. Sanduzzi A, Balbo P, Candoli P, Catapano GA, Contini P, Mattei A, Puglisi G, et al. COPD: adherence to therapy. Multidiscip Respir Med 201;9:60.
91. Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med 2011;105:435-41.
92. Zhang S, King D, Rosen VM, Ismaila AS. Impact of single combination inhaler versus multiple inhalers to deliver the same medications for patients with asthma or COPD: a systematic literature review. Int J Chron Obstruct Pulmon Dis 2020;15:417-38.
93. Rana RH, Alam K, Keramat SA, Gow J. Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review. Expert Rev Respir Med 2022;16:1067-84.
94. International Primary Care Respiratory Group (IPCRG). Variations in the pharmacological management of COPD due to payer-driven access criteria for triple therapy: Pan-European cross-expertise qualitative insights. https://www.ipcrg.org/24157 (2024).
95. Rothnie KJ, Wood RP, Czira A, Banks VL, Camidge LJ, Massey OKI, et al. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study. BMJ Open Respir Res 2024;11:e001890.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
How to Cite
